Recognition of live phosphatidylserine - labeled tumor cells by dendritic cells: A novel approach to immunotherapy of skin cancer

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2487-2496

  Shurin, Michael R ^a,b   Potapovich, Alia I ^c   Tyurina, Yulia Y ^c   Tourkova, Irina L ^a   Shurin, Galina V ^a   Kagan, Valerian E ^a,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; LIPOSOME; PHOSPHATIDYLSERINE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DISTRIBUTION; ENDOCYTOSIS; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METHODOLOGY; MOUSE MUTANT; SKIN TUMOR; T CELL LYMPHOMA;

ANIMALS; ANTIGEN PRESENTATION; DENDRITIC CELLS; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOMA, T-CELL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; PHOSPHATIDYLSERINES; SKIN NEOPLASMS;

EID: 65549115127     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2611     Document Type: Article

References (50)

1. Sjoblom T, Jones S( Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
2. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet 1999;23:387-8.
3. Palucka AR, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007;220:129-50.
4. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007;7:790-802.
5. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-203.
6. Banchereau J, Palucka AR. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5: 296-306.
7. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001;22:269-76.
8. Gahrilovich D. Mechanisms and functional signifl - cance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52.
9. Zhong H, Shurin MR, Han B. Optimizing dendritic cell-based immunotherapy for cancer. Expert Rev Vaccines 2007;6:333-45.
10. Jenne L, Arrighi JF, jonuleit H, Saurat JH, Hauser C. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res 2000;60:4446-52.
11. Russo V, Tanzarella S, Dalerba P, et al. Dendritic cells ac qui re the MAGE- 3 human an tumor antigen fro m apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci U S A 2000;97:2185-90.
12. Shaif- Muthana M, Mclntyre C, Sisley K, Rennie 1, Murray A. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res 2000;60:6441-7.
13. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate- pulsed dendritic cells. Nat Med 1998;4:328-32.
14. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998;95:9482-7.
15. Schnurr M, Scholz C, Rothenfusser S, et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and γ T cells. Cancer Res 2002;62:2347-52.
16. Inzkirweli N, Guckel B, Sohn C, Wallwiener D, Bastert G, Lindner M. Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates. Anticancer Res 2007;27:2121-9.
17. Urban BC, Willcox N, Roberts DJ. A role for CD36 in the regulation of dendritic cell function. Proc Natl Acad Sci USA 2001;98:8750-5.
18. Stuart LM, Lucas M, Simpson C, Lamb J, Savill j, Laey-Hulbert A. inhibitory effects of apoptotic cell ingestion upon endotoxin- driven myeloid dendritic cell maturation.) Immunol 2002;168:1627-35.
19. Ferguson TA, Herndon J, Elzey B, Griffith TS, Schoenberger S, Green DR. Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness, J Immunol 2002;168:5589-95.
20. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191: 423-34.
21. Wong OH, Huang FP, Chiang AK. Differential responses of cord and adult blood-derived dendritic cells to dying cells. Immunology 2005;116:13-20.
22. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 2001;61:8105-9.
23. Larmonier N, Merino D, Nicolas A, et al. Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis 2006;11: 1513-24.
24. Erwig LP, Henson PM. Clearance of apoptotic cells by phagocytes. Cell Death Differ 2007;15:243-50.
25. Gaipl US, Munoz LE, Rodel F, et al. Modulation of the immune system by dying cells and the phosphatidylserine- Iigand annexin A5. Autoimmunity 2007;40:254-9.
26. Fadok VA, Rratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphati- dylserine-speciflc clearance of apoptotic cells. Nature 2000;405:85-90.
27. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4 as a phosphatidyl- serine receptor. Nature 2007;450:435-9.
28. Park SY, Jung MY, Kim HJ, et al. Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ 2008;15:192-201.
29. Shurin GV, Tourkova IE, Chatta GS, et al. Small rho GTPases regulate antigen presentation in dendritic cells, j Immunol 2005;174:3394-400.
30. Roy MT, Gallardo M, Estelrieh J. Bilayer distribution of phosphatidylserine and phosphatidylethanolamine in lipid vesicles. Bioconjug Chem 1997;8:941-5.
31. Tanaka Y, Sehroit Aj. Insertion of fluorescent phosphatidylserine into the plasma membrane of red blood cells. Recognition by autologous macrophages, j Riol Chem 1983;258:11335-43.
32. Shurin MR, Shurin GV, Lokshin A, et al. Intratumoral eytokines/ ehemokines.growth factors and tumor infiltrating dendritic cells: friends or enemies?. Cancer Metastasis Rev 2006;25:333-56.
33. Folch j, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497-509.
34. Tyurina YY, Kawai K, Tyurin VA, Liu SX, Kagan VE, Fabisiak JP. The plasma membrane Is the site of selective phosphatidylserine oxidation during apoptosis: role of cytochrome C. Antioxid Redox Signal 2004;6:209-25.
35. Rottcher CJF, Van Gent CM, Pries C. A rapid and sensitive sub-micro phosphorous determination. Anal Chim Acta 1961;24:203-4.
36. Mandal D, Mazumder A, Das P, Kundu M, Rasu J. Fas-, caspase 8-, and caspase 3-dependent signaling regulates the activity of the aminophospholipid trans- locase and phosphatidylserine externalization in human erythrocytes, j Riol Chem 2005;280:39460-7.
37. Legitimo A, Consolini R, Failli A, et al. In vitro treatment of monocytes with 8-methoxypsolaren and ultraviolet A light induces dendritic cells with a tolerogenic phenotype. Clin Exp Immunol 2007;148: 564-72.
38. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Riol 2006;16:3-15.
39. Negus RP, Ralkwill FR. Cytokines in tumour growth, migration and metastasis. World J Urol 1996;14:157-65.
40. Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383-93.
41. Atkins MB. Cytokine-based therapy and bioehemo- therapy for advanced melanoma. Clin Cancer Res 2006; 12:2353-8s.
42. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Rrick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18:54-61.
43. Calorini L, Fallani A, Tombaccini D, Mugnai G, Ruggieri S. Lipid composition of cultured R16 melanoma cell variants with different lung-colonizing potential. Lipids 1987;22:651-6.
44. Daniels GA, Sanchez-Perez L, Diaz RM, et al. A simple method to cure established tumors by inflammatory killing of normal cells. Nat Riotechnol 2004;22: 1125-32.
45. Kobayashi N, Karisola P, Pena-Cruz V, et al. TIM-1 and TIM-4 Glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 2007;27: 927-40.
46. Santiago C, Ballesteros A, Martinez-Munoz L, et al. Structures of T cell immunoglobulin mucin protein 4 show a metal-ion-dependent ligand binding site where phosphatidylserine binds. Immunity 2007;27:941-51.
47. Girolomoni G, Pastore S, Zacchi V, Cavani A, Marconi A, Giannetti A. Phosphatidylserine enhances the ability of epidermal Langerhans cells to induce contact hypersensitivity. J Immunol 1993;150:4236-43.
48. Roof RW, Luescher IF, Unanue ER. Phospholipids enhance the binding of peptides to class II major histocompatibility molecules. Proc Natl Acad Sci USA 1990;87:1735-9.
49. Chen X, Doffek K, Sugg SL, Shilyansky j. Phosphatidylserine regulates the maturation of human dendritic cells. J Immunol 2004;173:2985-94.
50. Greenberg ME, Sun M, Zhang R, Febbraio M, Silverstein R, Hazen SL. Oxidized phosphatidylserine- CD36 interactions play an essential role in macrophage- dependent phagocytosis of apoptotic cells, j Exp Med 2006;203:2613-25.